Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma
NCT00591188Phase 2Completed
- Start
- Dec 2006
- Primary completion
- May 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and interferon alfa in renal cell carcinoma (RCC). Primary endpoint: Progression-Free Survival at 1 year. Started Dec 2006; status: completed.
02
Drugs
capecitabineinterferon alfa
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00591188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00591188.